BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER + HER2-metastatic breast cancer.

Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or ...

Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC ...

The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...

Throughout the year, members can sign-up to participate in virtual meetings focused on specific training or career topics. Members can select from a list of mentors per meeting topic. At the end of ...

The Resilience Skills Training Program aims to improve physician wellness in oncology through a proactive approach. The program targets current trainees to help create a culture change surrounding ...

The Association for Clinical Oncology (ASCO) works to ensure that all people with cancer have access to high-quality, affordable cancer care, no matter who they are or where they live. ASCO advocates ...

SABRE: Assessment of safety and efficacy of 64 Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.